Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
This study has been completed.
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborator:
Pfizer
Information provided by (Responsible Party):
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00929643
First received: June 26, 2009
Last updated: August 6, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial antibiotic empiric therapy on pharmacological and total healthcare costs for these patients in Greece.
| Condition | Intervention |
|---|---|
|
Complicated Intra-Abdominal Infection |
Other: no intervention |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | The Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections |
Resource links provided by NLM:
Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Primary Outcome Measures:
- Duration of Hospitalization [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]Overall health care resource utilization was analyzed using mean duration of hospitalization.
- Percentage of Participants With Initial Empiric Antibiotic Therapy (by Therapeutic Class) [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]
- Percentage of Participants With Failure of Initial Empiric Antibiotic Therapy [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]Failure of initial empiric therapy was assessed by an independent committee of qualified healthcare professionals (surgeon, and microbiologist specialist) and defined as requirement of additional antibiotic or change in antibacterial therapy on any day following the initial laparotomy, laparoscopy, or percutaneous drainage; or additional laparotomy, laparoscopy, or percutaneous drainage at least 2 days following the initial surgical/radiological intervention; or participant death due to infection.
- Duration of Hospitalization (by Failure of Initial Empiric Treatment) [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]Yes equals (=) initial empiric antibiotic treatment failed (additional antibiotic therapy or a change in antibacterial therapy was required following laparotomy/laparoscopy or percutaneous draininge or participant died due to infection); No=initial empiric antibiotic treatment successful (infectious process resolved and no change in initial empiric antibiotic therapy was required during the course of hospitalization except for stepdown therapy, de-escalation or intravenous to oral switch).
Secondary Outcome Measures:
- Percentage of Participants With Specific Pathogen [ Time Frame: Baseline up to 6 months ] [ Designated as safety issue: No ]
- Percentage of Participants by Diagnosis at Discharge [ Time Frame: Month 6 or study exit ] [ Designated as safety issue: No ]
| Enrollment: | 203 |
| Study Start Date: | November 2008 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| 1 |
Other: no intervention
success of the initial empiric treatment
|
Detailed Description:
Every patient diagnosed with complicated intra-abdominal infections will enter the study, until the pre-specified number of patients is reached. Patients diagnosed with any of conditions mentioned below (inclusion criteria) will enter the study, until the pre-specified number of patients is reached.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients hospitalized for complicated intra-abdominal infections
Criteria
Inclusion Criteria:
- A recorded primary diagnosis of a complicated intra-abdominal. infection (cIAI) and a procedure involving a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess The study will be a prospective, multi-centre, epidemiological study of patients (aged > 18 years) diagnosed with a complicated intra-abdominal infection AND who received a procedure involving laparotomy/laparoscopy or percutaneous drainage of an intra-abdominal abscess. cIAI's will include the following conditions/ diagnoses:
- Gastric ulcer with perforation;
- Gastric ulcer with hemorrhage and perforation;
- Duodenal ulcer with perforation;
- Duodenal ulcer with hemorrhage and perforation;
- Peptic ulcer with perforation;
- Peptic ulcer with hemorrhage and perforation;
- Gastrojejunal ulcer with perforation;
- Gastrojejunal ulcer with hemorrhage and perforation;
- Acute appendicitis with generalized peritonitis;
- Acute appendicitis with peritoneal abscess;
- Peritonitis;
- Abscess of intestine;
- Fistula of intestine, excluding rectum and anus;
- Ulceration of intestine;
- Perforation of intestine;
- Abscess of liver; or
- Acute cholecystitis with perforation.
The initial antibiotic regimen will be defined as all IV antibiotics newly received either on the day immediately prior to laparotomy or laparoscopy or percutaneous drainage of an intra-abdominal abscess, or on the day of these procedures, given that the use of these procedures prior to initiation of IV antibiotic regimens in complicated IAIs , which is increasingly common, is likely reflective of prophylaxis.
Exclusion Criteria:
- Patients not signing an informed consent form.
- Patients participating in another interventional study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00929643
Locations
| Greece | |
| Pfizer Investigational Site | |
| Haidari, Athens, Greece, 124 62 | |
| Pfizer Investigational Site | |
| Holargos, Athens, Greece, 115 27 | |
| Pfizer Investigational Site | |
| Marousi, Athens, Greece, 151 26 | |
| Pfizer Investigational Site | |
| N. Ionia, Athens, Greece, 142 33 | |
| Pfizer Investigational Site | |
| Peireus, Athens, Greece, 184 54 | |
| Pfizer Investigational Site | |
| Rio, Patras, Greece, 26500 | |
| Pfizer Investigational Site | |
| Herakleion, Vrete, Greece, 70013 | |
| Pfizer Investigational Site | |
| Athens, Greece, 115 24 | |
| Pfizer Investigational Site | |
| Athens, Greece, 115 26 | |
| Pfizer Investigational Site | |
| Thessaloniki, Greece, 56429 | |
| Pfizer Investigational Site | |
| Thessaloniki, Greece, 546 42 | |
| Pfizer Investigational Site | |
| Thessaloniki, Greece, 546 35 | |
| Pfizer Investigational Site | |
| Thessaloniki, Greece, 54636 | |
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Wyeth is now a wholly owned subsidiary of Pfizer |
| ClinicalTrials.gov Identifier: | NCT00929643 History of Changes |
| Other Study ID Numbers: | 3074A1-102311, B1811060 |
| Study First Received: | June 26, 2009 |
| Results First Received: | June 27, 2012 |
| Last Updated: | August 6, 2012 |
| Health Authority: | Greece: National Organization of Medicines |
Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
|
health care costs Intra-Abdominal Infection |
ClinicalTrials.gov processed this record on June 18, 2013